RVTY

SEC Filing Summary: PerkinElmer, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The request metadata listed "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended March 28, 2004. PerkinElmer operates in three reporting segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. The company provides scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental, and industrial markets.

Key Financial Metrics

Margins: Gross margin decreased slightly to 38.6% (from 38.8% in Q1 2003). Operating margin improved to approximately 7.0% (from 5.4%).

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 10% ($35.1 million) year-over-year. This was driven by a 34% increase in Fluid Sciences sales, a 7% increase in Life and Analytical Sciences, and a 4% increase in Optoelectronics. Approximately $18.0 million of the sales increase was attributable to favorable foreign exchange rates (primarily the Euro).
• Profitability: Net income increased significantly to $13.3 million from $2.4 million. Operating income rose 43% due to productivity improvements from restructuring and higher sales volume.
• Debt Reduction: The company prepaid $45.0 million on its term loan and $32.5 million on zero-coupon convertible notes (in the prior year comparison context, though the 2004 cash flow shows $45M term loan prepayment). Total debt decreased by approximately $45 million during the quarter.
• Restructuring: The company recorded a net restructuring and impairment charge of $1.2 million, primarily related to an impairment of the Optoelectronics Electroform product line. This contrasts with a $0.4 million reversal in the prior year.

Guidance, Outlook, and Risks

• Cost Savings: Management targets additional pre-tax cost savings of $5 million to $20 million in fiscal 2004 from the integration of Life Sciences and Analytical Instruments, aiming for a total of $30 million to $45 million relative to 2002 levels.
• Capital Expenditures: The company anticipates investing approximately $30.0 million to $40.0 million in capital expenditures for fiscal 2004.
• Dividends: A quarterly cash dividend of $0.07 per share was declared.
• Risks and Contingencies:
  • Legal: The company faces potential indemnification claims from L-3 Communications regarding litigation related to the September 11, 2001 attacks involving a sold business unit. The company cannot estimate the potential loss.
  • Environmental: An accrual of $6.0 million exists for environmental remediation, with potential exposure over ten years.
  • Debt Covenants: The company is subject to financial covenants regarding leverage and interest coverage ratios. Non-compliance could trigger an event of default.
  • Market Volatility: Results are sensitive to cyclical downturns in pharmaceutical, semiconductor, and aerospace markets, as well as foreign exchange fluctuations.

Investor Verification Checklist

• Debt Structure: Verify the impact of the interest rate swap on $100 million of 8 7/8% notes and the remaining balance on the senior credit facility ($200 million term loan).
• Restructuring Progress: Monitor the execution of the Q4 2002 and Q2 2003 restructuring plans to ensure targeted cost savings are realized.
• Legal Exposure: Track developments in the L-3 Communications indemnification claim regarding 9/11 litigation.
• Segment Performance: Assess the sustainability of the 34% sales growth in the Fluid Sciences segment.
• Foreign Exchange: Evaluate the sensitivity of future earnings to Euro and other currency fluctuations, given that over 50% of sales are international.